Status:
UNKNOWN
Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Indications for Warfarin Therapy
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Interethnic differences in warfarin dose requirements in the Asian population have been well described. Our previous studies showed that warfarin maintenance doses in our multi-ethnic population were ...
Detailed Description
Hypothesis: We hypothesize that warfarin dose requirement could be more accurately predicted using a simplified genotyping procedure requiring the identification of a single CYP2C9 allele and a single...
Eligibility Criteria
Inclusion
- At least 18 years of age
- New indication for warfarin therapy
- No previous history of liver disease; transaminases must be less than 3 times upper limit of normal and bilirubin within normal range
- No previous history of malabsorption syndrome or chronic diarrheal conditions
- Written, informed consent
Exclusion
- Uncontrolled hypertension
- Peptic ulcer disease
- Any other medical conditions as deemed unfit for warfarin therapy based on clinical judgement of primary physician
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2017
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT00700895
Start Date
August 1 2006
End Date
August 1 2017
Last Update
June 7 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Malaya Medical Centre
Kuala Lumpur, Malaysia, 50603
2
National University Hospital
Singapore, Singapore